Guangdong VTR Bio-Tech Co Ltd Asset Resilience Ratio
Guangdong VTR Bio-Tech Co Ltd asset resilience ratio. Guangdong VTR Bio-Tech Co Ltd (300381) has an Asset Resilience Ratio of 4.98% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300381 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Guangdong VTR Bio-Tech Co Ltd (2014–2025)
Asset resilience ratio of Guangdong VTR Bio-Tech Co Ltd from 2014 to 2025. This chart shows how Guangdong VTR Bio-Tech Co Ltd's Asset Resilience Ratio has changed over time. Read Guangdong VTR Bio-Tech Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Guangdong VTR Bio-Tech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 300381 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥143.28 Million | 4.98% |
| Total Liquid Assets | CN¥143.28 Million | 4.98% |
Asset Resilience Insights
- Limited Liquidity: Guangdong VTR Bio-Tech Co Ltd maintains only 4.98% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guangdong VTR Bio-Tech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guangdong VTR Bio-Tech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Guangdong VTR Bio-Tech Co Ltd Asset Resilience Ratio by Year (2014–2025)
Guangdong VTR Bio-Tech Co Ltd asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Guangdong VTR Bio-Tech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.79% | CN¥198.72 Million ≈ $29.08 Million |
CN¥2.92 Billion ≈ $428.01 Million |
-4.47pp |
| 2024-12-31 | 11.26% | CN¥332.13 Million ≈ $48.60 Million |
CN¥2.95 Billion ≈ $431.47 Million |
-6.95pp |
| 2023-12-31 | 18.21% | CN¥563.70 Million ≈ $82.49 Million |
CN¥3.09 Billion ≈ $452.89 Million |
-3.50pp |
| 2022-12-31 | 21.72% | CN¥688.89 Million ≈ $100.81 Million |
CN¥3.17 Billion ≈ $464.18 Million |
+21.56pp |
| 2016-12-31 | 0.16% | CN¥5.00 Million ≈ $731.66K |
CN¥3.21 Billion ≈ $469.70 Million |
-12.30pp |
| 2014-12-31 | 12.46% | CN¥120.04 Million ≈ $17.57 Million |
CN¥963.36 Million ≈ $140.97 Million |
-- |
About Guangdong VTR Bio-Tech Co Ltd
Guangdong VTR Bio-Tech Co., Ltd. researches, develops, produces, sells, and services bio-enzyme preparations, biosynthetics, and nutrition and health products in China and internationally. The company offers animal nutrition and health, biofuel, detergent, food and beverage, brewing, starch sweetness, bakery, plant extracts, pulp and paper, and textile enzymes, as well as biotechnology solutions.… Read more